Together with our previous report showing synergistic antileukemic activity of IFNα and BV6 in AML, a hematological malignancy [9], our present study provides evidence showing that this dual immunotherapy approach is of general relevance across cancers. The gene discussed is IFNA2; the disease is cancer.